SCHEMBL2652939

SCHEMBL2652939

CCCOCc1ccc2c(c1)ncn2-c1cccc(-c2ccon2)c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 10/20 0.44
GABRA1 P14867 2/20 0.38
GABRG2 P18507 2/20 0.38
GABRB3 P28472 2/20 0.38
GABRA5 P31644 2/20 0.38
GABRA3 P34903 2/20 0.38
GABRA2 P47869 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP19A1 P11511 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
KMT2A Q03164 1/20 0.36
SRC P12931 3/20 0.36
HPGD P15428 2/20 0.36
KDR P35968 1/20 0.35
KIT P10721 1/20 0.35
FLT3 P36888 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2659825 0.92 GABRA1 (0.41) FGFR1GABRA1GABRG2GABRB3GABRA5
SCHEMBL2655787 0.88 FGFR1 (0.40) FGFR1GABRA1GABRG2GABRB3GABRA5
SCHEMBL2662068 0.86 FGFR1 (0.40) FGFR1GABRA1GABRG2GABRB3GABRA5
SCHEMBL2653488 0.85 FGFR1 (0.38) FGFR1GABRA1GABRG2GABRB3GABRA5
SCHEMBL2654538 0.83 FGFR1 (0.45) FGFR1GABRA1GABRG2GABRB3GABRA5
SCHEMBL2654510 0.83 GABRA1 (0.40) FGFR1GABRA1GABRG2GABRB3GABRA5
SCHEMBL2654500 0.82 FGFR1 (0.45) FGFR1GABRA1GABRG2GABRB3GABRA5
SCHEMBL2654536 0.81 FGFR1 (0.43) FGFR1GABRA1GABRG2GABRB3GABRA5
SCHEMBL2654499 0.79 FGFR1 (0.51) FGFR1KMT2ASRCHPGD
SCHEMBL2653526 0.79 FGFR1 (0.44) FGFR1GABRA1GABRG2GABRB3GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060069135-A1 Benzimidazole derivatives and their use for modulating the gaba-a receptor complex NEUROSEARCH A/S (DK) 2006-03-30 US claimed
EP-1613618-A2 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA- sb A /sb RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2006-01-11 EP claimed
WO-2004087690-A2 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-A RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2004-10-14 WO claimed
US-20060069135-A1 Benzimidazole derivatives and their use for modulating the gaba-a receptor complex NEUROSEARCH A/S (DK) 2006-03-30 US disclosed
EP-1613618-A2 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA- sb A /sb RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2006-01-11 EP disclosed
WO-2004087690-A2 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-A RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2004-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069135-A1 Benzimidazole derivatives and their use for modulating the gaba-a receptor complex GABRB2, GABRB1, GABRB3 FGFR1 3374/4885GABRA1 6/4885GABRG2 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.